ACRS - Aclaris Therapeutics, Inc.
3.52
0 0%
Share volume: 2,387,986
Last Updated: 03-27-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.18%
PREVIOUS CLOSE
CHG
CHG%
$3.52
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-07-2024 | 08-07-2024 | 11-06-2024 | 02-27-2025 | 05-08-2025 | 08-07-2025 | 11-06-2025 | 02-26-2026 | |
| Assets | |||||||||
| Total Assets | 174.065 M | 161.071 M | 182.394 M | 220.327 M | 198.094 M | 189.147 M | 175.534 M | 160.460 M | |
| Current Assets | 135.338 M | 117.635 M | 132.330 M | 125.951 M | 108.790 M | 104.202 M | 100.592 M | 96.316 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 4.680 M | 5.565 M | |
| Short Term Investments | 92.325 M | 88.259 M | 80.071 M | 89.024 M | 74.957 M | 74.404 M | 70.656 M | 70.791 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 35.841 M | 22.834 M | 47.651 M | 24.570 M | 30.357 M | 25.402 M | 25.256 M | 19.960 M | |
| Total Non-current Assets | 33.199 M | 38.778 M | 45.714 M | 90.302 M | 85.211 M | 81.084 M | 71.297 M | 60.612 M | |
| Property Plant Equipment | 1.531 M | 1.293 M | 1.133 M | 1.008 M | 942.000 K | 868.000 K | 811.000 K | 761.000 K | |
| Other Assets | 37.196 M | 42.143 M | 48.931 M | 93.368 M | 88.362 M | 84.077 M | 74.131 M | 63.383 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 174.065 M | 161.071 M | 182.394 M | 220.327 M | 198.094 M | 189.147 M | 175.534 M | 160.460 M | |
| Total liabilities | 32.051 M | 27.249 M | 52.243 M | 64.773 M | 54.028 M | 57.408 M | 55.434 M | 57.378 M | |
| Total current liabilities | 20.080 M | 15.682 M | 18.816 M | 31.596 M | 21.514 M | 26.839 M | 25.631 M | 28.645 M | |
| Accounts Payable | 10.810 M | 7.269 M | 7.662 M | 4.690 M | 6.354 M | 8.797 M | 9.187 M | 13.158 M | |
| Other liabilities | 11.971 M | 11.567 M | 12.245 M | 13.139 M | 13.308 M | 12.351 M | 12.311 M | 12.565 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 11.971 M | 11.567 M | 12.245 M | 13.139 M | 13.308 M | 12.351 M | 12.311 M | 12.565 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 142.014 M | 133.822 M | 130.151 M | 155.554 M | 144.066 M | 131.739 M | 120.100 M | 103.082 M | |
| Common stock | 930.115 M | 933.008 M | 936.033 M | 1.058 B | 1.062 B | 1.065 B | 1.067 B | 1.070 B | |
| Retained earnings | -787.737 M | -798.723 M | -806.309 M | -902.861 M | -917.946 M | -933.375 M | -947.989 M | -967.784 M |